Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Nov 12 - Nov 17
Starkebaum and Harlan, 1986
The first head-to-head clinical trial (SURMOUNT-5, published in NEJM 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide approximately 47% greater relative weight loss
While additional research is needed to determine how GLP-1 RAs put a person at an increased risk for NAION, it may be linked to fluctuations in blood pressure and blood sugar, diabetes-related vascular issues, and low blood sugar (hypoglycemia) caused by Mounjaro
Heart and mitochondria*
Another goal of the study is to discover if this malfunction is related to an orexinergic deficiency and whether orexin-A may be used to restore it
Why Start Treatments Through ApexBlood No Bloodwork Required (But Recommended): While bloodwork isnt required to access treatments, we strongly encourage comprehensive lab testing within the past year
